1.1 Scope of Research

1.2 Research Methodology

1.2 Research Methodology (Continued)

1.3 Key Findings

2.1 Diabetes and Obesity Disorders Contribute to Global Mortality

2.2 Biomarker Platforms Lead Diverse Clinical and Research Applications

2.3 Metabolomic and Proteomic Biomarker Assays Dominate the Technology Landscape

2.4 Biomarkers Impact Diagnostic and Treatment Efficacy Applications across Diabetes and Obesity

3.1 Summary of Key Industry Drivers and Restraints

3.2 Industry Growth Likely to Be Fueled by Rising Demand for Personalized Medicine

3.3 Biomarker Validation Likely to Limit Industry Growth

3.4 Summary of Key Technology Drivers and Restraints

3.5 Rapid Technological Advances are Likely to Drive the Growth of Novel Biomarker Platforms

3.6 False Positive Results across Biomarker Studies are a Major Setback

4.1 Biomarker Research Fuels Novel Scientific Discoveries

4.2 Steady Growth in Biomarker Research Publications

4.3 Significant Research Funding for Diabetes Biomarkers

4.4 Metabolomic Biomarkers Likely to Emerge across Type 2 Diabetes and Obesity

4.5 Metabolomic Biomarkers Likely to Emerge across Diabetes and Related Complications

5.1 Exploring Novel Diagnostic Biomarkers for Diabetes

5.2 Novel Metabolomic Biomarker Panel for Diabetes

5.3 Comprehensive Biomarker Testing Services Platform

5.4 New Prognostic Biomarker for Diabetic Nephropathy

5.5 Novel Assay for Diabetic Kidney Disease

5.6 Advanced Glycation End Products as Diagnostic Biomarkers

5.7 Novel Metabolomic Biomarker Profiling Platform

6.1 Obesity and Diabetes Biomarker Discoveries are Likely to Fuel Novel Therapies

6.2 Ongoing Late Phase Clinical Studies are Indicative of the Emerging Potential of Diabetes and Obesity Biomarkers

6.3 Biomarkers Likely to Play a Larger Role in Diabetes Management

6.4 Biomarkers Fuel Drug Target Studies across Diabetes and Obesity

6.5 Companion Diagnostic Platform for Obesity Treatment

6.6 Novel Companion Diagnostic Platform for Diabetes Management

7.1 Research and Development Partnerships Dominate the Collaborative Landscape

7.2 Key Research and Development Partnerships

7.3 Key Collaborations for Service Platforms, Product Licensing, and Commercialization

7.4 North America Dominates the Regional Landscape for Biomarker Technologies across Diabetes and Obesity Indications

7.5 Technology Roadmap

8.1 Patent Research Scope and Concepts

8.2 Patent Applications for Diabetes and Obesity Biomarkers Likely to Increase in the Future

8.3 US Leads the Global Patent Landscape for Diabetes and Obesity Biomarkers

8.4 Life Science Companies Dominate the Patent Landscape

9.1 Growth Opportunity 1: Point-of-Care Diagnostics

9.2 Growth Opportunity 2: Personalized Medicine

9.3 Growth Opportunity 2: Patient Risk Stratification

9.4 Strategic Imperatives for Success and Growth

10.1 Key Contacts

Legal Disclaimer

11.1 The Frost & Sullivan Story

11.2 Value Proposition: Future of Your Company & Career

11.3 Global Perspective

11.4 Industry Convergence

11.5 360º Research Perspective

11.6 Implementation Excellence

11.7 Our Blue Ocean Strategy